(1) Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med 1952; 13:597-614.

(2) Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19(5):647-672.

(3) Carey RM, Varma SK, Drake CR, Jr., Thorner MO, Kovacs K, Rivier J, Vale W. Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study. N Engl J Med 1984; 311(1):13-20.

(4) Samuels MH, Loriaux DL. Cushing's syndrome and the nodular adrenal gland. Endocrinol Metab Clin North Am 1994; 23(3):555-569.

(5) Young WF, Jr., Carney JA, Musa BU, Wulffraat NM, Lens JW, Drexhage HA. Familial Cushing's syndrome due to primary pigmented nodular adrenocortical disease. Reinvestigation 50 years later. N Engl J Med 1989; 321(24):1659-1664.

(6) Lacroix A, Bolte E, Tremblay J, Dupre J, Poitras P, Fournier H, Garon J, Garrel D, Bayard F, Taillefer R, . Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome. N Engl J Med 1992; 327(14):974-980.

(7) Orth DN. Cushing's syndrome. N Engl J Med 1995; 332(12):791-803.

(8) Ross EJ, Linch DC. Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2(8299):646-649.

(9) Weber A, Trainer PJ, Grossman AB, Afshar F, Medbak S, Perry LA, Plowman PN, Rees LH, Besser GM, Savage MO. Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43(1):19-28.

(10) Wajchenberg BL, Mendonca BB, Liberman B, Pereira MA, Carneiro PC, Wakamatsu A, Kirschner MA. Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 1994; 15(6):752-787.

(11) Popovic V, Micic D, Nesovic M, Howlett T, Doniach I, Kendereski A, Djordjevic P, Manojlovic D, Micic J, Besser M. Cushing's disease cycling over ten years. Exp Clin Endocrinol 1990; 96(2):143-148.

(12) Nieman LK, Cutler GB, Jr. The sensitivity of the urine free cortisol measurement as a screening test for Cushing's syndrome. Program of the 72nd Annual Meeting of The Endocrine Society, Atlanta GA (Abstract P-822) . 1-1-1990.

Ref Type: Abstract

(13) Yanovski JA, Cutler GB, Jr., Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 1993; 269(17):2232-2238.

(14) Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA. Urinary free cortisol excretion in depression. Psychol Med 1976; 6(1):43-50.

(15) Vila R, Granada ML, Guitierrez RM, Fernandez-Lopez JA, Remesar X, Formiguera X, Foz M, Alemany M. Urinary free cortisol excretion pattern in morbid obese women. Endocr Res 2001; 27(1-2):261-268.

(16) Liddle GW. Tests of pituitary-adrenal suppressability in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20:1539-1560.

(17) Kennedy L, Atkinson AB, Johnston H, Sheridan B, Hadden DR. Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing's syndrome. Br Med J (Clin Res Ed) 1984; 289(6453):1188-1191.

(18) Hankin ME, Theile HM, Steinbeck AW. An evaluation of laboratory tests for the detection and differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1977; 6(3):185-196.

(19) Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43(5):545-550.

(20) Nugent CA, Nichols T, Tyler FH. Diagnosis of Cushing's syndrome-single dose dexamethasone suppression test. Arch Intern Med 1965;(116):172-176.

(21) Shimizu N, Yoshida H. Studies on the "low dose" suppressible Cushing's disease. Endocrinol Jpn 1976; 23(6):479-484.

(22) McHardy-Young S, Harris PW, Lessof MH, Lyne C. Singledose dexamethasone suppression test for Cushing's Syndrome. Br Med J 1967; 2(554):740-744.

(23) Seidensticker JF, Folk RL, Wieland RG, Hamwi GJ. Screening test for Cushing's syndrome with plasma 11- hydroxycorticosteroids. JAMA 1967; 202(2):87-90.

(24) Crapo L. Cushing's syndrome: a review of diagnostic tests. Metabolism 1979; 28(9):955-977.

(25) Odagiri E, Demura R, Demura H, Suda T, Ishiwatari N, Abe Y, Jibiki K, Shizume K. The changes in plasma cortisol and urinary free cortisol by an overnight dexamethasone suppression test in patients with Cushing's disease. Endocrinol Jpn 1988; 35(6):795-802.

(26) Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B. Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome--recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 1997; 34 ( Pt 3):222-229.

(27) Putignano P, Kaltsas GA, Satta MA, Grossman AB. The effects of anti-convulsant drugs on adrenal function. Horm Metab Res 1998; 30(6-7):389-397.

(28) Papanicolaou DA, Mullen N, Kyrou I, Nieman LK. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2002; 87(10):4515-4521.

(29) Putignano P, Toja P, Dubini A, Giraldi FP, Corsello SM, Cavagnini F. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. J Clin Endocrinol Metab 2003; 88(9):4153-4157.

(30) Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab 1998; 83(8):2681-2686.

(31) Castro M, Elias PC, Quidute AR, Halah FP, Moreira AC. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 1999; 84(3):878-882.

(32) Gafni RI, Papanicolaou DA, Nieman LK. Nighttime salivary cortisol measurement as a simple, noninvasive, outpatient screening test for Cushing's syndrome in children and adolescents. J Pediatr 2000; 137(1):30-35.

(33) Martinelli CE, Jr., Sader SL, Oliveira EB, Daneluzzi JC, Moreira AC. Salivary cortisol for screening of Cushing's syndrome in children. Clin Endocrinol (Oxf) 1999; 51(1):67-71.

(34) Viardot A, Huber P, Puder JJ, Zulewski H, Keller U, Muller B. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab 2005; 90(10):5730-5736.

(35) Trilck M, Flitsch J, Ludecke DK, Jung R, Petersenn S. Salivary cortisol measurement--a reliable method for the diagnosis of Cushing's syndrome. Exp Clin Endocrinol Diabetes 2005; 113(4):225-230.

(36) Yaneva M, Mosnier-Pudar H, Dugue MA, Grabar S, Fulla Y, Bertagna X. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab 2004; 89(7):3345-3351.

(37) Liu H, Bravata DM, Cabaccan J, Raff H, Ryzen E. Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf) 2005; 63(6):642-649.

(38) Trainer PJ, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 34(4):317-330.

(39) Papanicolaou DA, Yanovski JA, Cutler GB, Chrousos GP, Nieman LK. A single midnight cortisol measurement discriminates Cushing's syndrome from pseudo-Cushing's states. program of the 76th Annual Meeting of the Endocrine Society, Anaheim CA Abstract P-1270. 1994.

Ref Type: Abstract

(40) Yanovski JA, Cutler GB, Jr., Chrousos GP, Nieman LK. Prospective evaluation of the dexamethasone-suppressed corticotrophin-releasing hormone test in the differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. program of the 77th Annual Meeting of the Endocrine Society, Washington DC p 99 (abstract). 1995.

Ref Type: Abstract

(41) Coiro V, Volpi R, Capretti L, Caffarri G, Chiodera P. Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome. J Intern Med 2000; 247(6):667-673.

(42) Moro M, Putignano P, Losa M, Invitti C, Maraschini C, Cavagnini F. The desmopressin test in the differential diagnosis between Cushing's disease and pseudo-Cushing states. J Clin Endocrinol Metab 2000; 85(10):3569-3574.

(43) Pecori GF, Pivonello R, Ambrogio AG, De Martino MC, de Martin M, Scacchi M, Colao A, Toja PM, Lombardi G, Cavagnini F. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) 2007; 66(2):251-257.

(44) Martin NM, Dhillo WS, Banerjee A, Abdulali A, Jayasena CN, Donaldson M, Todd JF, Meeran K. Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2006; 91(7):2582-2586.

(45) Butler PW, Besser GM. Pituitary-adrenal function in severe depressive illness. Lancet 1968; 1(7554):1234-1236.

(46) Fig LM, Gross MD, Shapiro B, Ehrmann DA, Freitas JE, Schteingart DE, Glazer GM, Francis IR. Adrenal localization in the adrenocorticotropic hormone-independent Cushing syndrome. Ann Intern Med 1988; 109(7):547-553.

(47) Perry RR, Nieman LK, Cutler GB, Jr., Chrousos GP, Loriaux DL, Doppman JL, Travis WD, Norton JA. Primary adrenal causes of Cushing's syndrome. Diagnosis and surgical management. Ann Surg 1989; 210(1):59-68.

(48) Doppman JL, Miller DL, Dwyer AJ, Loughlin T, Nieman L, Cutler GB, Chrousos GP, Oldfield E, Loriaux DL. Macronodular adrenal hyperplasia in Cushing disease. Radiology 1988; 166(2):347-352.

(49) Doppman JL, Travis WD, Nieman L, Miller DL, Chrousos GP, Gomez MT, Cutler GB, Jr., Loriaux DL, Norton JA. Cushing syndrome due to primary pigmented nodular adrenocortical disease: findings at CT and MR imaging. Radiology 1989; 172(2):415-420.

(50) Malchoff CD, Rosa J, DeBold CR, Kozol RA, Ramsby GR, Page DL, Malchoff DM, Orth DN. Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: an unusual cause of Cushing's syndrome. J Clin Endocrinol Metab 1989; 68(4):855-860.

(51) Doppman JL, Nieman LK, Travis WD, Miller DL, Cutler GB, Jr., Chrousos GP, Norton JA. CT and MR imaging of massive macronodular adrenocortical disease: a rare cause of autonomous primary adrenal hypercortisolism. J Comput Assist Tomogr 1991; 15(5):773-779.

(52) Sohaib SA, Hanson JA, Newell-Price JD, Trainer PJ, Monson JP, Grossman AB, Besser GM, Reznek RH. CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome. AJR Am J Roentgenol 1999; 172(4):997-1002.

(53) Aron DC, Findling JW, Fitzgerald PA, Brooks RM, Fisher FE, Forsham PH, Tyrrell JB. Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature. Am J Med 1981; 71(2):302-306.

(54) Smals AG, Pieters GF, van Haelst UJ, Kloppenborg PW. Macronodular adrenocortical hyperplasia in long-standing Cushing's disease. J Clin Endocrinol Metab 1984; 58(1):25-31.

(55) Newell-Price J, Morris DG, Drake WM, Korbonits M, Monson JP, Besser GM, Grossman AB. Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2002; 87(4):1640-1645.

(56) Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM. Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf) 1986; 24(6):699-713.

(57) Stewart PM, Walker BR, Holder G, O'Halloran D, Shackleton CH. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995; 80(12):3617-3620.

(58) Putignano P, Kaltsas GA, Korbonits M, Jenkins PJ, Monson JP, Besser GM, Grossman AB. Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatment. J Clin Endocrinol Metab 2000; 85(9):3309-3312.

(59) Howlett TA, Grossman A, Rees LH, Besser GM. Differential diagnosis of Cushing's syndrome. Lancet 1986; 2(8511):871.

(60) Nieman LK, Chrousos GP, Oldfield EH, Avgerinos PC, Cutler GB, Jr., Loriaux DL. The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann Intern Med 1986; 105(6):862-867.

(61) Grossman AB, Howlett TA, Perry L, Coy DH, Savage MO, Lavender P, Rees LH, Besser GM. CRF in the differential diagnosis of Cushing's syndrome: a comparison with the dexamethasone suppression test. Clin Endocrinol (Oxf) 1988; 29(2):167-178.

(62) Dichek HL, Nieman LK, Oldfield EH, Pass HI, Malley JD, Cutler GB, Jr. A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1994; 78(2):418-422.

(63) Tyrrell JB, Findling JW, Aron DC, Fitzgerald PA, Forsham PH. An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. Ann Intern Med 1986; 104(2):180-186.

(64) Bruno OD, Rossi MA, Contreras LN, Gomez RM, Galparsoro G, Cazado E, Kral M, Leber B, Arias D. Nocturnal high-dose dexamethasone suppression test in the aetiological diagnosis of Cushing's syndrome. Acta Endocrinol (Copenh) 1985; 109(2):158-162.

(65) Isidori AM, Kaltsas GA, Mohammed S, Morris DG, Jenkins P, Chew SL, Monson JP, Besser GM, Grossman AB. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2003; 88(11):5299-5306.

(66) Trainer PJ, Faria M, Newell-Price J, Browne P, Kopelman P, Coy DH, Besser GM, Grossman AB. A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. J Clin Endocrinol Metab 1995; 80(2):412-417.

(67) Trainer PJ, Woods RJ, Korbonits M, Popovic V, Stewart PM, Lowry PJ, Grossman AB. The pathophysiology of circulating corticotropin-releasing hormone- binding protein levels in the human. J Clin Endocrinol Metab 1998; 83(5):1611-1614.

(68) Nieman LK, Oldfield EH, Wesley R, Chrousos GP, Loriaux DL, Cutler GB, Jr. A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1993; 77(5):1308-1312.

(69) Giraldi FP, Invitti C, Cavagnini F. The corticotropin-releasing hormone test in the diagnosis of ACTH- dependent Cushing's syndrome: a reappraisal. Clin Endocrinol (Oxf) 2001; 54(5):601-607.

(70) Invitti C, Giraldi FP, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84(2):440-448.

(71) Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, Trainer PJ. The growth hormone secretagogue hexarelin stimulates the hypothalamo- pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 1999; 84(7):2489-2495.

(72) Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, Grossman AB. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86(2):881-887.

(73) Tabarin A, San Galli F, Dezou S, Leprat F, Corcuff JB, Latapie JL, Guerin J, Roger P. The corticotropin-releasing factor test in the differential diagnosis of Cushing's syndrome: a comparison with the lysine-vasopressin test. Acta Endocrinol (Copenh) 1990; 123(3):331-338.

(74) Malerbi DA, Mendonca BB, Liberman B, Toledo SP, Corradini MC, Cunha-Neto MB, Fragoso MC, Wajchenberg BL. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1993; 38(5):463-472.

(75) Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, Lombardi G, Camanni F. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997; 82(8):2439-2444.

(76) Newell-Price J, Perry L, Medbak S, Monson J, Savage M, Besser M, Grossman A. A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1997; 82(1):176-181.

(77) Tsagarakis S, Tsigos C, Vasiliou V, Tsiotra P, Kaskarelis J, Sotiropoulou C, Raptis SA, Thalassinos N. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab 2002; 87(4):1646-1653.

(78) Korbonits M, Jacobs RA, Aylwin SJB, Burrin JM, Dahia PLM, Monson JP, Honegger J, Fahlbush R, Trainer PJ, Chew SL, Besser GM, Grossman AB. Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors. J Clin Endocrinol Metab 1998; 83(10):3624-3630.

(79) Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88(12):5593-5602.

(80) Hermus AR, Pieters GF, Pesman GJ, Smals AG, Benraad TJ, Kloppenborg PW. The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome. Lancet 1986; 2(8506):540-544.

(81) Woo YS, Isidori AM, Wat WZ, Kaltsas GA, Afshar F, Sabin I, Jenkins PJ, Monson JP, Besser GM, Grossman AB. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005; 90(8):4963-4969.

(82) Findling JW, Kehoe ME, Shaker JL, Raff H. Routine inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin (ACTH)-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome. J Clin Endocrinol Metab 1991; 73(2):408-413.

(83) Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, Cutler GB, Jr., Loriaux DL. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991; 325(13):897-905.

(84) Kaltsas GA, Giannulis MG, Newell-Price JD, Dacie JE, Thakkar C, Afshar F, Monson JP, Grossman AB, Besser GM, Trainer PJ. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84(2):487-492.

(85) Colao A, Faggiano A, Pivonello R, Giraldi FP, Cavagnini F, Lombardi G. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. Eur J Endocrinol 2001; 144(5):499-507.

(86) Swearingen B, Katznelson L, Miller K, Grinspoon S, Waltman A, Dorer DJ, Klibanski A, Biller BM. Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab 2004; 89(8):3752-3763.

(87) Yamamoto Y, Davis DH, Nippoldt TB, Young WF, Jr., Huston J, III, Parisi JE. False-positive inferior petrosal sinus sampling in the diagnosis of Cushing's disease. Report of two cases. J Neurosurg 1995; 83(6):1087-1091.

(88) McCance DR, McIlrath E, McNeill A, Gordon DS, Hadden DR, Kennedy L, Sheridan B, Atkinson AB. Bilateral inferior petrosal sinus sampling as a routine procedure in ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 1989; 30(2):157-166.

(89) Machado MC, de Sa SV, Domenice S, Fragoso MC, Puglia P, Jr., Pereira MA, de Mendonca BB, Salgado LR. The role of desmopressin in bilateral and simultaneous inferior petrosal sinus sampling for differential diagnosis of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2007; 66(1):136-142.

(90) Miller DL. Neurologic complications of petrosal sinus sampling. Radiology 1992; 183(3):878.

(91) Lefournier V, Gatta B, Martinie M, Vasdev A, Tabarin A, Bessou P, Berge J, Bachelot I, Chabre O. One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1999; 84(9):3401-3402.

(92) Rotman-Pikielny P, Patronas N, Papanicolaou DA. Pituitary apoplexy induced by corticotrophin-releasing hormone in a patient with Cushing's disease. Clin Endocrinol (Oxf) 2003; 58(5):545-549.

(93) Tabarin A, Greselle JF, San Galli F, Leprat F, Caille JM, Latapie JL, Guerin J, Roger P. Usefulness of the corticotropin-releasing hormone test during bilateral inferior petrosal sinus sampling for the diagnosis of Cushing's disease. J Clin Endocrinol Metab 1991; 73(1):53-59.

(94) Landolt AM, Schubiger O, Maurer R, Girard J. The value of inferior petrosal sinus sampling in diagnosis and treatment of Cushing's disease. Clin Endocrinol (Oxf) 1994; 40(4):485-492.

(95) Lefournier V, Martinie M, Vasdev A, Bessou P, Passagia JG, Labat-Moleur F, Sturm N, Bosson JL, Bachelot I, Chabre O. Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing's disease pituitary microadenoma: influence of catheter position and anatomy of venous drainage. J Clin Endocrinol Metab 2003; 88(1):196-203.

(96) Lienhardt A, Grossman AB, Dacie JE, Evanson J, Huebner A, Afshar F, Plowman PN, Besser GM, Savage MO. Relative contributions of inferior petrosal sinus sampling and pituitary imaging in the investigation of children and adolescents with ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2001; 86(12):5711-5714.

(97) Morris DG, Grossman AB. Dynamic tests in the diagnosis and differential diagnosis of Cushing's syndrome. J Endocrinol Invest 2003; 26(7 Suppl):64-73.

(98) Miller DL, Doppman JL, Nieman LK, Cutler GB, Jr., Chrousos G, Loriaux DL, Oldfield EH. Petrosal sinus sampling: discordant lateralization of ACTH-secreting pituitary microadenomas before and after stimulation with corticotropin-releasing hormone. Radiology 1990; 176(2):429-431.

(99) Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120(10):817-820.

(100) Findling JW, Doppman JL. Biochemical and radiologic diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 1994; 23(3):511-537.

(101) Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. Ann Intern Med 1990; 112(6):434-444.

(102) Escourolle H, Abecassis JP, Bertagna X, Guilhaume B, Pariente D, Derome P, Bonnin A, Luton JP. Comparison of computerized tomography and magnetic resonance imaging for the examination of the pituitary gland in patients with Cushing's disease. Clin Endocrinol (Oxf) 1993; 39(3):307-313.

(103) de Herder WW, Uitterlinden P, Pieterman H, Tanghe HL, Kwekkeboom DJ, Pols HA, Singh R, van de Berge JH, Lamberts SW. Pituitary tumour localization in patients with Cushing's disease by magnetic resonance imaging. Is there a place for petrosal sinus sampling? Clin Endocrinol (Oxf) 1994; 40(1):87-92.

(104) Buchfelder M, Nistor R, Fahlbusch R, Huk WJ. The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease. AJNR Am J Neuroradiol 1993; 14(5):1183-1190.

(105) Doppman JL, Pass HI, Nieman LK, Findling JW, Dwyer AJ, Feuerstein IM, Ling A, Travis WD, Cutler GB, Jr., Chrousos GP, . Detection of ACTH-producing bronchial carcinoid tumors: MR imaging vs CT. AJR Am J Roentgenol 1991; 156(1):39-43.

(106) de Herder WW, Lamberts SW. Tumor localization--the ectopic ACTH syndrome. J Clin Endocrinol Metab 1999; 84(4):1184-1185.

(107) Tabarin A, Valli N, Chanson P, Bachelot Y, Rohmer V, Bex-Bachellerie V, Catargi B, Roger P, Laurent F. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84(4):1193-1202.

(108) Torpy DJ, Chen CC, Mullen N, Doppman JL, Carrasquillo JA, Chrousos GP, Nieman LK. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 1999; 84(4):1186-1192.

(109) Lamberts SW, van der Lely AJ, de Herder WW. Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long-term follow-up. J Clin Endocrinol Metab 1995; 80(11):3111-3113.

(110) Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 1988; 109(6):487-493.

(111) Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 1995; 80(11):3114-3120.

(112) Blevins LS, Jr., Christy JH, Khajavi M, Tindall GT. Outcomes of therapy for Cushing's disease due to adrenocorticotropin- secreting pituitary macroadenomas. J Clin Endocrinol Metab 1998; 83(1):63-67.

(113) Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1996; 81(7):2647-2652.

(114) Ram Z, Nieman LK, Cutler GB, Jr., Chrousos GP, Doppman JL, Oldfield EH. Early repeat surgery for persistent Cushing's disease. J Neurosurg 1994; 80(1):37-45.

(115) Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Savage MO, Afshar F, Besser GM. Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf) 1993; 38(1):73-78.

(116) Toms GC, McCarthy MI, Niven MJ, Orteu CH, King TT, Monson JP. Predicting relapse after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1993; 76(2):291-294.

(117) Yap LB, Turner HE, Adams CB, Wass JA. Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf) 2002; 56(1):25-31.

(118) Hughes NR, Lissett CA, Shalet SM. Growth hormone status following treatment for Cushing's syndrome. Clin Endocrinol (Oxf) 1999; 51(1):61-66.

(119) Kelly PA, Samandouras G, Grossman AB, Afshar F, Besser GM, Jenkins PJ. Neurosurgical Treatment of Nelson's Syndrome. J Clin Endocrinol Metab 2002; 87(12):5465-5469.

(120) Valimaki M, Pelkonen R, Porkka L, Sivula A, Kahri A. Long-term results of adrenal surgery in patients with Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 1984; 20(2):229-236.

(121) Kemink L, Pieters G, Hermus A, Smals A, Kloppenborg P. Patient's age is a simple predictive factor for the development of Nelson's syndrome after total adrenalectomy for Cushing's disease. J Clin Endocrinol Metab 1994; 79(3):887-889.

(122) Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA, Besser GM. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1995; 80(1):165-171.

(123) Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab 2007; 92(1):172-179.

(124) Nagesser SK, van Seters AP, Kievit J, Hermans J, van Dulken H, Krans HM, van de Velde CJ. Treatment of pituitary-dependent Cushing's syndrome: long-term results of unilateral adrenalectomy followed by external pituitary irradiation compared to transsphenoidal pituitary surgery. Clin Endocrinol (Oxf) 2000; 52(4):427-435.

(125) Gagner M, Lacroix A, Bolte E. Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma. N Engl J Med 1992; 327(14):1033.

(126) McCallum RW, Connell JM. Laparoscopic adrenalectomy. Clin Endocrinol (Oxf) 2001; 55(4):435-436.

(127) Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997; 336(3):172-177.

(128) Seo Y, Fukuoka S, Takanashi M, Sasaki T, Suematsu K, Nakamura J. Gamma knife surgery for Cushing's disease. Surg Neurol 1995; 43(2):170-175.

(129) Wolffenbuttel BH, Kitz K, Beuls EM. Beneficial gamma-knife radiosurgery in a patient with Nelson's syndrome. Clin Neurol Neurosurg 1998; 100(1):60-63.

(130) Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER, Jr. Radiosurgery for Cushing's disease after failed transsphenoidal surgery. J Neurosurg 2000; 93(5):738-742.

(131) Magee BJ, Gattamaneni HR, Pearson D. Adrenal cortical carcinoma: survival after radiotherapy. Clin Radiol 1987; 38(6):587-588.

(132) de Castro F, Isa W, Aguera L, Rosell CD, Abad JI, Robles JE, Zudaire JJ, Berian JM. [Primary adrenal carcinoma]. Actas Urol Esp 1993; 17(1):30-34.

(133) Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, Allolio B. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91(11):4501-4504.

(134) He J, Zhou J, Lu Z. Radiotherapy of ectopic ACTH syndrome due to thoracic carcinoids. Chin Med J (Engl ) 1995; 108(5):338-341.

(135) Andres R, Mayordomo JI, Cajal S, Tres A. Paraneoplastic Cushing's syndrome associated to locally advanced thymic carcinoid tumor. Tumori 2002; 88(1):65-67.

(136) Carballeira A, Fishman LM, Jacobi JD. Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: correlation of in vivo and in vitro studies. J Clin Endocrinol Metab 1976; 42(4):687-695.

(137) Trainer PJ, Besser M. Cushing's syndrome. Therapy directed at the adrenal glands. Endocrinol Metab Clin North Am 1994; 23(3):571-584.

(138) Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 35(2):169-178.

(139) Connell JM, Cordiner J, Davies DL, Fraser R, Frier BM, McPherson SG. Pregnancy complicated by Cushing's syndrome: potential hazard of metyrapone therapy. Case report. Br J Obstet Gynaecol 1985; 92(11):1192-1195.

(140) Santen RJ, Van den BH, Symoens J, Brugmans J, DeCoster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 1983; 57(4):732-736.

(141) Pont A, Goldman ES, Sugar AM, Siiteri PK, Stevens DA. Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med 1985; 145(8):1429-1431.

(142) Engelhardt D, Dorr G, Jaspers C, Knorr D. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klin Wochenschr 1985; 63(13):607-612.

(143) Engelhardt D, Weber MM, Miksch T, Abedinpour F, Jaspers C. The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin Endocrinol (Oxf) 1991; 35(2):163-168.

(144) Steen RE, Kapelrud H, Haug E, Frey H. In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour. Acta Endocrinol (Copenh) 1991; 125(3):331-334.

(145) Chou SC, Lin JD. Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease. Endocr J 2000; 47(4):401-406.

(146) Ahmed M, Kanaan I, Alarifi A, Ba-Essa E, Saleem M, Tulbah A, McArthur P, Hessler R. ACTH-producing pituitary cancer: experience at the King Faisal Specialist Hospital & Research Centre. Pituitary 2000; 3(2):105-112.

(147) Rickman T, Garmany R, Doherty T, Benson D, Okusa MD. Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma. Am J Kidney Dis 2001; 37(4):838-846.

(148) Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 1984; 86(3):503-513.

(149) McCance DR, Ritchie CM, Sheridan B, Atkinson AB. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet 1987; 1(8532):573.

(150) Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 1991; 35(4):347-352.

(151) Tucker WS, Jr., Snell BB, Island DP, Gregg CR. Reversible adrenal insufficiency induced by ketoconazole. JAMA 1985; 253(16):2413-2414.

(152) Miettinen TA. Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 1988; 29(1):43-51.

(153) Young RB, Bryson MJ, Sweat ML, Street JC. Complexing of DDT and o,p'DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem 1973; 4(6):585-591.

(154) Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25(7):891-897.

(155) Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356(23):2372-2380.

(156) Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, . Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322(17):1195-1201.

(157) Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 1980; 92(5):613-619.

(158) Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia. Q J Med 1992; 84(305):671-679.

(159) Haak HR, Caekebeke-Peerlinck KM, van Seters AP, Briet E. Prolonged bleeding time due to mitotane therapy. Eur J Cancer 1991; 27(5):638-641.

(160) Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983; 1(8336):1270.

(161) Weber MM, Lang J, Abedinpour F, Zeilberger K, Adelmann B, Engelhardt D. Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis. Clin Investig 1993; 71(11):933-938.

(162) Lamberts SW, Bons EG, Bruining HA, de Jong FH. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther 1987; 240(1):259-264.

(163) De Coster R, Beerens D, Haelterman C, Wouters L. Effects of etomidate on cortisol biosynthesis in isolated guinea-pig adrenal cells: comparison with metyrapone. J Endocrinol Invest 1985; 8(3):199-202.

(164) Allolio B, Stuttmann R, Fischer H, Leonhard W, Winkelmann W. Long-term etomidate and adrenocortical suppression. Lancet 1983; 2(8350):626.

(165) Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C, Winkelmann W. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr 1988; 66(8):361-364.

(166) Herrmann BL, Mitchell A, Saller B, Stolke D, Forsting M, Frilling A, Mann K. [Transsphenoidal hypophysectomy of a patient with an ACTH-producing pituitary adenoma and an "empty sella" after pretreatment with etomidate]. Dtsch Med Wochenschr 2001; 126(9):232-234.

(167) Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab 1998; 83(10):3542-3544.

(168) Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab 2001; 86(9):4104-4108.

(169) Greening JE, Brain CE, Perry LA, Mushtaq I, Sales MJ, Grossman AB, Savage MO. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res 2005; 64(3):140-143.

(170) Waveren Hogervorst CO, Koppeschaar HP, Zelissen PM, Lips CJ, Garcia BM. Cortisol secretory patterns in Cushing's disease and response to cyproheptadine treatment. J Clin Endocrinol Metab 1996; 81(2):652-655.

(171) Sonino N, Fava GA, Fallo F, Franceschetto A, Belluardo P, Boscaro M. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary 2000; 3(2):55-59.

(172) Mercado-Asis LB, Yasuda K, Murayama M, Mune T, Morita H, Miura K. Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol Jpn 1992; 39(4):385-395.

(173) Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004; 89(5):2452-2462.

(174) Lamberts SW, de Herder WW, Krenning EP, Reubi JC. A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. J Clin Endocrinol Metab 1994; 78(1):17-19.

(175) Colao A, Pivonello R, Tripodi FS, Orio F, Jr., Ferone D, Cerbone G, Di Somma C, Merola B, Lombardi G. Failure of long-term therapy with sodium valproate in Cushing's disease. J Endocrinol Invest 1997; 20(7):387-392.

(176) Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006; 91(11):4482-4488.

(177) Boscaro M, Atkinson AB, Bertherat J, Petersenn S, Glusman JE, Tran LL. SOM230 Cushing's disease study group. Early data on the efficacy and safety of the novel multi-ligand somatostatin analog SOM230 in patients with Cushing's disease. 87th Annual Meeting of The Endocrine Society, San Diego, CA, June 4-7, 2005, P2-672 . 2005.

Ref Type: Abstract

(178) Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, Arzt E, Stalla GK. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001; 108(8):1123-1131.

(179) Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002; 8(11):1281-1287.

(180) Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003; 111(9):1381-1388.

(181) Cannavo S, Arosio M, Almoto B, Dall'Asta C, Ambrosi B. Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease. Clin Endocrinol (Oxf) 2005; 63(1):118-119.

(182) Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004; 151(2):173-178.

(183) Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 2005; 90(3):1340-1346.

(184) Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J. Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab 2007; 92(5):1758-1763.

(185) Baulieu EE. The steroid hormone antagonist RU486. Mechanism at the cellular level and clinical applications. Endocrinol Metab Clin North Am 1991; 20(4):873-891.

(186) Healy DL, Chrousos GP, Schulte HM, Gold PW, Hodgen GD. Increased adrenocorticotropin, cortisol, and arginine vasopressin secretion in primates after the antiglucocorticoid steroid RU 486: dose response relationships. J Clin Endocrinol Metab 1985; 60(1):1-4.

(187) Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985; 61(3):536-540.

(188) Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton JP. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab 1986; 63(3):639-643.

(189) Trainer PJ, Eastment C, Grossman AB, Wheeler MJ, Perry L, Besser GM. The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome. Clin Endocrinol (Oxf) 1993; 39(4):441-443.

(190) Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001; 86(1):117-123.

(191) Swearingen B, Biller BM, Barker FG, Katznelson L, Grinspoon S, Klibanski A, Zervas NT. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med 1999; 130(10):821-824.

(192) Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB. Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 2004; 89(12):6348-6357.

(193) Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40(4):479-484.

(194) Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84(8):2664-2672.

(195) Pecori GF, Moro M, Cavagnini F. Gender-related differences in the presentation and course of Cushing's disease. J Clin Endocrinol Metab 2003; 88(4):1554-1558.

(196) Storr HL, Chan LF, Grossman AB, Savage MO. Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends Endocrinol Metab 2007; 18(4):167-174.

(197) Wick MR, Rosai J. Neuroendocrine neoplasms of the thymus. Pathol Res Pract 1988; 183(2):188-199.

(198) Dimopoulos MA, Fernandez JF, Samaan NA, Holoye PY, Vassilopoulou-Sellin R. Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer 1992; 69(1):66-71.